FIELD: immunology.
SUBSTANCE: disclosed is an antibody and its antigen-binding fragment, which specifically bind to the domain Pre-S1 of the surface antigen of hepatitis B virus (HBV). What is also described is a nucleic acid, an expression vector and a cell for expression of the antibody or its antigen-binding fragment.
EFFECT: this group of inventions can find application in prevention, treatment or diagnostics of HBV-infection.
9 cl, 1 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| SPECIFIC ANTIBODIES TO PD-L1 AND METHODS FOR THEIR APPLICATION | 2017 |
|
RU2749109C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| ANTI-VSIG4 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF | 2020 |
|
RU2826236C1 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
